TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: earlier return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Tumor reduction percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of complete regression of tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: overall state of balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: facial esthetic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: γH2AX foci levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: %FLICA readouts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of social functioning measures
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Rate of re-hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in sadness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increase in anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mucosal visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vasodilator responses to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vasoconstrictor responses to L-NMMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: E-RS total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mobilization of CD34+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mobilization of WBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of BL-8040
Endpoint domain: Adverse events/effects
Primary endpoint: Cataract development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Compliance during the period of 'fdp'
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: client wait time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retention in treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VEV assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck Depression Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intercellular adhesion molecule-1 (ICAM-1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in SVRI from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ascites control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: job dissatisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: poor co-worker relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: 5-year survival probability for cardiomyopathy
Endpoint domain: Mortality/survival
Primary endpoint: 1-year survival probability from lung cancer
Endpoint domain: Mortality/survival
Primary endpoint: Onset of psychotic symptoms
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients returning to routine activities within 1 day
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to return to work
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: abdominal circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Platelet response to clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clopidogrel nonresponders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in clinical symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole blood viscosity at high shear rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tear stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular surface status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NIS-LL values at month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum Uric Acid (UA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients achieving target AP <140/90 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean AP lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total number of common cold illnesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load in nasal lavages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bacterial vaginosis (BV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: PANSS positive symptom subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with positive qualitative CMV PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increases in CMV viral load at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vertebral bone mineral content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertebral fracture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in papules/pustules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in non-inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum S100B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severe neurological impairment
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory thresholds measured by ASSR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target vessel revascularization
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma levels of C3a and thrombin-antithrombin III complexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Parameters of fibrinolysis, tissue-type plasminogen activator, and plasminogen activator inhibitor type 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neutrophil elastase-alpha 1-antitrypsin complexes and phospholipase A2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical cure and microbiological clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual recurrence rate of H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absorption times after nebulization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HbA1c < 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total cost for diabetes-related care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ulcer healing within 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean rocuronium dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Systemic levels of estradiol, estrone, and estrone sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC0‐24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: stage 2 sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of 8‐iso‐PGF2α
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved gait coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in physical symptoms or state of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exhaled NO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: forced expiratory volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Iodine dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: competitive employment outcomes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean post-void residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: International Index of Erectile Function - Erectile Function domain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom scoring improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tear meniscus height improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in use of artificial tear supplements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: VISA-A scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Downregulation of uterine contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polyamine levels in gastric mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PMS symptom improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median incision-related in-hospital stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in neck, shoulders, and lower back pains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in range of motion (ROM) of hips, neck, knees, and shoulders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in perceived exertion scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Pressure pain threshold increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total acupuncture sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported abstinence from alcohol and cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative urine tests for cocaine metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Addiction Severity Index drug and alcohol use composite scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute differences in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute differences in head circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute differences in length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of hearing improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Happiness scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SF-36 physical functioning score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF-36 role-physical score change
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 6MWD distance walked change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subsequent progressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: role function
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Thresholds for vibration perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: end-of-period PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Opioid dose requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue analgesia needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: atrial arrhythmia recurrence-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Mortality associated with female sex
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of allergic skin reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severity of allergic skin reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pregnancy Rate (PR) per cycle of IUI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Knowledge about cervical cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of HPV risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distant disease-free survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac failure
Endpoint domain: Adverse events/effects
Primary endpoint: Change in lipid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: inflammation and oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: days of febrile neutropenia avoided
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: days of neutropenia (ANC <1.0 × 10(9)/L) avoided
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: days of thrombopenia (platelets <20 × 10(9)/L) avoided
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of definitive diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: average number of recommended diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: average number of unacceptable diagnoses
Endpoint domain: Adverse events/effects
Primary endpoint: Body fat change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent body fat change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fasting serum lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: skin microvascular perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of older adults meeting screening criteria for predementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: epilepsy self-management scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in SANS and SAPS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate exceeding 120 bpm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VEGF concentrations in aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEDF levels in aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of residual graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant stability quotient (ISQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of myocardial infarctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Days at hospital for cardiovascular reasons
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Postanaesthetic shivering cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receiver operating characteristics area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pre-PCI corrected TIMI frame count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of normal pre-PCI TIMI myocardial perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients surviving at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with a functioning graft at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Cost per survivor at 10 years
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tissue coring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of MRD ≥10-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial thromboembolic events (TEs)
Endpoint domain: Adverse events/effects
Primary endpoint: recurrence-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Learning about and delivering BMT
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: interviewer-rated PTSS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: global psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: leak rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gallbladder area decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average spontaneous vaginal deliveries per month per health facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: child immunizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average number of HIV tests for pregnant women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PCR-corrected day 28 cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction of local fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in PBPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reestablishment of coital function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to Peak Torque (TTP) for isokinetic strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Torque Development (RTD) for isometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Torque Development (RTD) for isokinetic strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chronic obstructive pulmonary disease self-efficacy scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: scar surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: latency to relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sunbathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer sunburns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased use of protective clothing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nonfatal myocardial infarction (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in CAPS-total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in CAPS-D subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in HAM-A score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PANSS-P score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Demand for cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective 'feel drug' effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective 'dislike drug' effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spontaneous restoration rate of sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on complement 3 (C3) and TNF‐α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes